0.00
price down icon100.00%   -2.7271
after-market  After Hours:  2.7271  2.7271   +
loading
Procaps Group S.A stock is currently priced at $0.00, with a 24-hour trading volume of 0. It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.69 pivot point. If it approaches the $2.50 support level, significant changes may occur.
Previous Close:
$2.7271
Open:
$0
24h Volume:
0
Market Cap:
$307.68M
Revenue:
$414.10M
Net Income/Loss:
$52.20M
P/E Ratio:
0.00
EPS:
0.6525
Net Cash Flow:
$34.06M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1D Range:
Value
$0.00
$0.00
52W Range:
Value
$0.00
$4.95

Procaps Group S.A Stock (PROC) Company Profile

Name
Name
Procaps Group S.A
Name
Phone
356 7995 6138
Name
Address
9 rue de Bitbourg, Luxembourg City
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2023-12-04
Name
Latest SEC Filings
Name
PROC's Discussions on Twitter

Procaps Group S.A Stock (PROC) Financials Data

Procaps Group S.A (PROC) Revenue 2024

PROC reported a revenue (TTM) of $414.10 million for the quarter ending September 30, 2023, a -4.80% decline year-over-year.
loading

Procaps Group S.A (PROC) Net Income 2024

PROC net income (TTM) was $52.20 million for the quarter ending September 30, 2023, a -13.15% decrease year-over-year.
loading

Procaps Group S.A (PROC) Cash Flow 2024

PROC recorded a free cash flow (TTM) of $34.06 million for the quarter ending September 30, 2023, a +252.50% increase year-over-year.
loading

Procaps Group S.A (PROC) Earnings per Share 2024

PROC earnings per share (TTM) was $0.52 for the quarter ending September 30, 2023, a -6.84% decline year-over-year.
loading
Procaps Group, S.A. operates as an integrated healthcare and pharmaceutical company worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately ten therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg City, Luxembourg.
$13.26
price up icon 1.69%
$73.26
price up icon 1.57%
$55.92
price up icon 0.22%
drug_manufacturers_specialty_generic RDY
$74.55
price up icon 0.72%
$135.99
price down icon 1.28%
$11.57
price up icon 0.87%
Cap:     |  Volume (24h):